Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Opens Manufacturing, Services Facility in Iceland

NEW YORK, March 19 - Wisconsin-based genomics company NimbleGen Systems on Tuesday said it has opened an office in Iceland that will manufacture custom DNA arrays and provide services for customers in North America and Europe.

"The new Iceland facility allows us to penetrate several key markets ... for the biopharmaceutical and academic research markets," Mike Treble, president and CEO of NimbleGen, said in a statement.

The facility, which will manufacturing but not R&D responsibilities, cost about $1 million and three months to complete, Treble told GenomeWeb during a pause in a business trip to the UK. It will eventually employ between 15 and 20 staff, all of whom will be Icelanders

Though a local manager will oversee the day-to-day operations of the new facility, David Cooper, chief medical officer and senior vice president of services at NimbleGen, will be responsible for the site and will visit it regularly.

Helping to create the Icelandic unit, called NimbleGen Systems of Iceland, or utibu a Islandi, was a collaboration inked early in the year with UVS, a subsidiary of Iceland Genomics. In this collaboration, UVS was given access to NimbleGen's microarray technology for its cancer research.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.